Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, ...

NeurIPS, the biggest AI research conference, turned Vancouver’s convention center into a battleground for wooing AI talent.

Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.

Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, ...

An FDA advisory committee on Friday voted 8 to 4 in favor of Japan-based Seikagaku's condoliase injection for the treatment ...

Metsera files for IPO, developing GLP-1 drug MET-097i and other obesity treatments to compete with Eli Lilly and Novo Nordisk ...

Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...

Repare Therapeutics pauses gynecologic cancer drugs lunresertib & camonsertib, shifts focus to early-stage assets RP-1664 & ...

China legislation have asked the US Commerce Department to harden its policies around who can run clinical trials at sites ...

Eli Lilly is expanding its private financing ambitions, partnering with venture capital firm Andreessen Horowitz on a new ...

Moderna CSO, launches Kerna Labs with $6M seed funding to develop AI models for better mRNA drugs, partnering with Julia Peng ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...